## FORM 4

obligations may continue. See

Instruction 1(b)

Check this box if no longer subject to Section 16. Form 4 or Form 5

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERS	HIP
---	-----

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Davidson David  (Last) (First) (Middle)  C/O BLUEBIRD BIO, INC.  150 SECOND STREET						2. Issuer Name and Ticker or Trading Symbol bluebird bio, Inc. [ BLUE ]									tionship of Reportir all applicable) Director Officer (give title		10% O		wner	
						3. Date of Earliest Transaction (Month/Day/Year) 03/15/2016									Officer (give title below)  Chief Medical Officer				эреспу	
(Street) CAMBRIDGE MA 02141					_	4. If Amendment, Date of Original Filed (Month/Day/Year)								Indivine)	vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person					
(City)	(S		(Zip)   e   -	Non-Deriv	vative	e Sec	urit	ies Δ	cauire	-d D	oisnosed (	of or B	enefici	ally	Owner	1				
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			5. Amoun		unt of es ially Following	Forn (D) c	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership				
						Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3	ction(s)			(Instr. 4)				
Common Stock			03/15/2	/2016				M		1,000	A	\$2.0	9	10	10,600		D			
Common	Stock	03/15/20			016	16			S <sup>(1)</sup>		800	D	\$45.96	9648(2)		9,800		D		
Common Stock 03/15/2			)16				<b>S</b> <sup>(1)</sup>		200	D	\$46.76	5.7675 <sup>(3)</sup>		9,600		D				
		Т	able								sposed of , converti				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	eemed tion Date, h/Day/Year)	n Date, Trans Code		of Deri Sec Acq (A) ( Disp of (I	oosed D) tr. 3, 4	6. Date Expira (Month	tion D		7. Title a Amount Securitie Underlyi Derivatir (Instr. 3	of es ing /e Security	De Se (In	Price of erivative ecurity 1str. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerci	sable	Expiration Date	Title	Amoun or Numbe of Shares	er						
Stock Option (right to	\$2.09	03/15/2015			M	M		1,000	(4	)	04/13/2022	Common	1,000	\$0.00		35,239		D		

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 14, 2015.
- 2. The range of prices for the transaction reported on this line was \$45.60 to \$46.50. The average weighted price was \$45.9648. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 3. The range of prices for the transaction reported on this line was \$46.65 to \$46.89. The average weighted price was \$46.7675. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 4. This option vests over a four-year period, at a rate of twenty-five percent (25%) on February 13, 2013 and in 36 equal monthly installments thereafter.

## Remarks:

/s/Jason F. Cole, Attorney-in-

03/17/2016

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.